AstraZeneca received FDA approval for Truqap (capivasertib) combined with abiraterone and prednisone to treat PTEN-deficient metastatic prostate cancer, marking the first targeted therapy for this group. The approval was based on Phase III trial data showing a 19% reduction in disease progression or death risk and a 7.5-month improvement in progression-free survival. Additionally, the FDA granted Priority Review to Ultomiris for treating immunoglobulin A nephropathy, based on positive Phase 3 trial results showing significant proteinuria reduction. These developments highlight AstraZeneca's expanding role in targeted cancer and kidney disease therapies.
The Frost & Sullivan Institute has recognized 50 leading companies with the 2026 Visionary Growth Leadership Best Practices Recognition for embedding innovation, measurable impact, and sustainability into their growth strategies. These companies, inc...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
